A Phase 1 Single Dose PK Study in Adolescent Subjects With Fragile X Syndrome or Angelman Syndrome
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Sep 2017
At a glance
- Drugs Gaboxadol (Primary)
- Indications Angelman syndrome; Fragile X syndrome
- Focus Pharmacokinetics
- Sponsors Ovid Therapeutics
- 14 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Jun 2017 According to an Ovid Therapeutics media release, the company expects topline data to be available in the second half of 2017.
- 13 Apr 2017 New trial record